RecruitingNCT06821386

N-Care Project: Enhancing Asian-Pacific Collaboration


Sponsor

National Taiwan University Hospital

Enrollment

70 participants

Start Date

Feb 17, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

Through Asian-Pacific multinational collaboration, we aim to utilize third-generation genome sequencing to rapidly diagnose genetic diseases in critically ill infants and young children, achieving the goal of early diagnosis for targeted treatment.


Eligibility

Max Age: 18 Months

Inclusion Criteria12

  • Age: infant/newborn less than 18 months
  • Admitted to intensive care unit
  • At least one of the following conditions A. Specific anomaly highly suggestive of a genetic etiology
  • Multiple birth defects
  • Single major malformation that required intervention (surgery or medication)
  • Significantly abnormal EKG
  • Significant hypotonia
  • B. Children with high-risk stratification on assessment of a Brief Resolved Unexplained Event (BRUE) with any of the following:
  • Recurrent severe infection events
  • Recurrent or prolonged seizures
  • Unexplained cardiopulmonary resuscitation (CPR)
  • Suspect inborn error of metabolism

Exclusion Criteria4

  • Infants with a definitive non-genetic diagnosis: ex as below A. An infection with normal response to therapy B. Isolated prematurity C. Transient hypoglycemia D. Isolated unconjugated hyperbilirubinemia E. Isolated Transient Neonatal Tachypnea F. Those where the clinical course can be explained without genetic testing
  • Confirmed genetic diagnosis explains illness
  • Lack of consent: Families who do not consent to genetic testing or data sharing.
  • Infants without sufficient DNA sample quality/quantity: Where the quality or quantity of the DNA sample is inadequate for sequencing.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTGenetic study with nanopore sequencing

The study targets critically ill children under 18 months of age, employing third-generation genome sequencing technology to complete long-read sequencing within 8-11 days, analyzing single nucleotide variants, small insertions/deletions, and structural variations. Through this research, we aim to enhance diagnostic accuracy, enabling ICUs to provide personalized and precision care and treatment based on genetic information, thereby ensuring a greater level of health security for these children. We only draw 3-5cc whole blood once for exam.


Locations(1)

National Taiwan University Hospital

Taipei, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06821386


Related Trials